Chapter 36 — Antiviral Pharmacology — Module 1 — HIV Pharmacology Part 1: NRTIs and NNRTIs
1. A clinician observes that a regimen pairing a nucleoside reverse transcriptase inhibitor (NRTI) with an integrase inhibitor maintains suppression even when a dose is occasionally late, while the same lateness with certain other agents risks failure. Integrating NRTI activation pharmacology, which principle best explains the relative forgiveness of the NRTI component specifically?
A) NRTIs are highly protein-bound, buffering free drug concentration after a missed dose
B) NRTIs are eliminated unchanged by the kidney, so plasma levels persist for days
C) The antiviral effect depends on the intracellular triphosphate, whose half-life is often substantially longer than the parent drug's plasma half-life, so activity persists across a delayed dose
D) NRTIs irreversibly destroy reverse transcriptase, so the enzyme cannot recover regardless of dosing
E) NRTIs are continuously regenerated from an inactive depot in adipose tissue
ANSWER: C
Rationale:
The NRTI antiviral effect is exerted by the intracellular triphosphate, not the parent drug in plasma. Because the triphosphate half-life is frequently much longer than the plasma half-life (for example lamivudine's intracellular triphosphate persists about 10 to 19 hours versus a 5-to-7-hour plasma half-life, and emtricitabine's is roughly 39 hours), antiviral activity carries across a delayed dose. This integrates the activation and pharmacokinetic concepts established earlier.
Option A: Option A is incorrect: forgiveness derives from intracellular triphosphate persistence, not plasma protein binding.
Option B: Option B is incorrect: renal elimination does not extend the intracellular active species, and several NRTIs require renal dose reduction precisely because they are cleared.
Option D: Option D is incorrect: NRTIs cause chain termination during reverse transcription rather than permanently destroying the enzyme.
Option E: Option E is incorrect: there is no adipose depot regenerating active drug; persistence is intracellular triphosphate half-life.
2. A researcher proposes that combining tenofovir with zidovudine might constrain the evolution of NRTI resistance because the resistance pathways for the two drugs interfere with each other. Integrating the mechanisms of K65R and thymidine analogue mutations (TAMs), which explanation supports this proposal?
A) K65R (selected by tenofovir) reduces the efficiency of the excision reaction that TAMs (selected by zidovudine) rely upon, so selecting one pathway antagonizes the other, limiting simultaneous high-level resistance to both
B) K65R and TAMs are the same mutation, so a virus can never carry tenofovir and zidovudine resistance together
C) Both drugs share an identical resistance mutation that reverts to wild type under combination pressure
D) Zidovudine prevents tenofovir from being phosphorylated, so resistance cannot develop to either
E) TAMs enhance K65R selection, accelerating combined resistance and making the pair inadvisable
ANSWER: A
Rationale:
TAMs promote resistance by enhancing reverse transcriptase excision of the incorporated chain terminator through pyrophosphorolysis; K65R reduces the efficiency of that excision. Because the two pathways are largely mutually antagonistic, selecting one impairs the other, which is the integrative basis for the reciprocal susceptibility between tenofovir and zidovudine resistance.
Option B: Option B is incorrect: K65R and TAMs are distinct mutations, not the same change; the relationship is functional antagonism, not identity.
Option C: Option C is incorrect: the drugs do not share one revert-prone mutation; they select different pathways.
Option D: Option D is incorrect: zidovudine does not block tenofovir phosphorylation; the interaction is at the level of resistance mechanisms.
Option E: Option E inverts the relationship: the pathways antagonize rather than reinforce one another.
3. A patient on efavirenz is prescribed a new oral agent that is known to be extensively metabolized by CYP3A4 and has a narrow therapeutic window at the low end (loss of efficacy if underexposed). Integrating efavirenz's enzyme effects, what net outcome should be anticipated and why?
A) Efavirenz will inhibit CYP3A4 and raise the new agent's level, risking toxicity
B) Efavirenz will have no metabolic effect because it is itself a CYP3A4 substrate
C) The new agent will induce efavirenz metabolism, lowering efavirenz to subtherapeutic levels
D) Efavirenz will block renal clearance of the new agent, causing accumulation
E) Efavirenz will induce CYP3A4 and accelerate metabolism of the new agent, lowering its concentration and risking loss of efficacy, so dose adjustment or an alternative is needed
ANSWER: E
Rationale:
Efavirenz is a CYP3A4 inducer; a co-administered drug that is a CYP3A4 substrate will be metabolized faster, lowering its plasma concentration. For an agent that loses efficacy when underexposed, this predicts therapeutic failure, so the dose must be adjusted upward or an alternative chosen. This integrates induction direction with substrate dependence.
Option A: Option A inverts the mechanism: efavirenz induces rather than inhibits CYP3A4.
Option B: Option B is incorrect: although efavirenz is partly a substrate, its clinically dominant effect on co-medications is CYP3A4 induction.
Option C: Option C reverses the direction of the interaction: efavirenz induces the co-medication's metabolism, not the other way around in a way that lowers efavirenz.
Option D: Option D is incorrect: the interaction is hepatic enzyme induction, not blockade of renal clearance.
4. A patient with documented M184V (methionine to valine at codon 184) on the genotype is being switched to a new regimen. The specialist deliberately retains lamivudine even though M184V confers high-level lamivudine resistance. Integrating the consequences of M184V, what is the strongest pharmacological rationale for keeping lamivudine?
A) M184V silently reverts to wild type once lamivudine is reintroduced, restoring full activity
B) M184V imposes a viral fitness cost and sustains increased susceptibility to companion agents such as tenofovir and zidovudine; maintaining the mutation pressure can keep the virus less fit and the partner drugs more effective
C) Lamivudine independently suppresses HIV at a different enzyme, so resistance at reverse transcriptase is irrelevant
D) Retaining lamivudine eliminates the need for any other active agent in the regimen
E) M184V converts lamivudine into an integrase inhibitor, providing a second mechanism
ANSWER: B
Rationale:
M184V reduces viral replicative fitness and is associated with sustained increased susceptibility to tenofovir, zidovudine, and abacavir. Retaining lamivudine maintains selective pressure for M184V, which keeps the virus less fit and the companion NRTIs more effective; this integrative reasoning underlies the common practice of keeping lamivudine or emtricitabine despite the resistance call.
Option A: Option A is incorrect: M184V does not silently revert while drug pressure continues.
Option C: Option C is incorrect: lamivudine acts at reverse transcriptase, so its resistance there is directly relevant, not irrelevant.
Option D: Option D is incorrect: a fully active regimen still requires other active agents; retaining one resistant-but-useful drug does not substitute for them.
Option E: Option E is incorrect: M184V does not transform lamivudine into an integrase inhibitor.
5. An older patient on tenofovir disoproxil fumarate (TDF) with a cobicistat-boosted third agent is started on a chronic nonsteroidal anti-inflammatory drug (NSAID) for arthritis. Integrating the transporter biology and exposure effects, why does this combination carry an especially high risk of tenofovir nephrotoxicity?
A) The NSAID alone is nephrotoxic; tenofovir and cobicistat contribute nothing
B) Cobicistat lowers tenofovir exposure while the NSAID raises it, so the effects cancel out
C) All three agents are eliminated by the liver, so the kidney is not involved
D) Cobicistat raises plasma tenofovir by inhibiting tubular secretion, the NSAID both reduces renal perfusion and competes at proximal tubular transport, and advanced age adds risk, so multiple mechanisms converge to increase proximal tubular tenofovir injury
E) The NSAID converts tenofovir alafenamide into tenofovir disoproxil fumarate, increasing toxicity
ANSWER: D
Rationale:
Several risk factors stack here: cobicistat inhibits transporter-mediated tubular secretion of tenofovir and raises its plasma exposure; NSAIDs reduce renal perfusion through prostaglandin inhibition and compete at proximal tubular transport; and advanced age is an independent risk factor. Integrating these, the convergence markedly increases the risk of proximal tubular tenofovir injury, warranting close renal monitoring or a switch to tenofovir alafenamide.
Option A: Option A is incorrect: tenofovir and the booster are central contributors, not bystanders.
Option B: Option B is incorrect: cobicistat raises rather than lowers tenofovir, so the effects compound rather than cancel.
Option C: Option C is incorrect: tenofovir handling is renal, and the toxicity is a tubular event.
Option E: Option E is incorrect: the patient is on TDF, and NSAIDs do not interconvert the two tenofovir prodrugs.
6. A patient of African ancestry on standard-dose efavirenz develops unusually severe and persistent central nervous system (CNS) symptoms. Integrating efavirenz metabolism with its toxicity profile, which mechanism best explains this presentation?
A) A CYP2B6 slow-metabolizer genotype (such as the 516G>T variant) raises efavirenz plasma concentrations, and because efavirenz CNS toxicity is concentration-dependent, slow metabolizers experience more severe and prolonged symptoms
B) Efavirenz induces its own metabolism so completely that levels fall, paradoxically worsening CNS effects through withdrawal
C) The symptoms reflect an immune hypersensitivity reaction unrelated to drug concentration
D) Rapid CYP2B6 metabolism lowers efavirenz levels, and low levels cause the most severe CNS toxicity
E) CNS toxicity is purely idiosyncratic and bears no relationship to efavirenz pharmacokinetics
ANSWER: A
Rationale:
Efavirenz is metabolized primarily by CYP2B6, which is highly polymorphic; slow-metabolizer variants such as 516G>T (more common in individuals of African ancestry) produce efavirenz concentrations several-fold higher than in extensive metabolizers. Because efavirenz CNS toxicity is concentration-dependent, slow metabolizers experience more severe and persistent symptoms, integrating the pharmacogenomic and toxicity concepts.
Option B: Option B is incorrect: the issue is high concentrations from slow metabolism, not a withdrawal phenomenon from autoinduction.
Option C: Option C is incorrect: efavirenz CNS toxicity tracks concentration rather than being an immune hypersensitivity.
Option D: Option D inverts the relationship: slow (not rapid) metabolism raises levels, and high (not low) levels drive toxicity.
Option E: Option E is incorrect: the toxicity is concentration-related and not purely idiosyncratic.
7. First-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as efavirenz lose activity with a single binding-pocket mutation, whereas second-generation agents such as doravirine tolerate several common mutations. Integrating the structural mechanism of NNRTI binding with the concept of genetic barrier, which statement best explains the difference?
A) Second-generation NNRTIs are incorporated into viral DNA, so point mutations cannot affect them
B) Second-generation NNRTIs require intracellular phosphorylation, which bypasses the mutated pocket
C) NNRTIs bind a flexible allosteric pocket; first-generation agents make rigid contacts easily disrupted by a single substitution (low genetic barrier), while later-generation agents bind more adaptively and retain affinity despite common mutations (higher genetic barrier)
D) Second-generation NNRTIs act at the active site rather than the allosteric pocket, avoiding resistance entirely
E) The allosteric pocket does not exist in resistant virus, so only wild-type virus can be treated
ANSWER: C
Rationale:
All NNRTIs bind a flexible hydrophobic allosteric pocket near the polymerase site. First-generation agents make relatively rigid contacts that a single substitution (for example K103N) can disrupt, giving a low genetic barrier; later-generation agents bind more adaptively and retain affinity across several common mutations, giving a higher genetic barrier. This integrates binding structure with the resistance-barrier concept.
Option A: Option A is incorrect: NNRTIs are not incorporated into DNA; that is the NRTI mechanism.
Option B: Option B is incorrect: NNRTIs require no phosphorylation, so that cannot explain the difference.
Option D: Option D is incorrect: second-generation NNRTIs still bind the allosteric pocket, not the active site.
Option E: Option E is incorrect: the pocket exists in resistant virus, but mutations alter binding affinity rather than abolishing the pocket.
8. A treatment-naive patient is started on a three-drug regimen without baseline genotype testing. The patient unknowingly harbors transmitted K103N. Integrating the concepts of transmitted resistance and functional monotherapy, what outcome is most likely if the third agent is efavirenz?
A) Full suppression, because three drugs were prescribed regardless of resistance
B) Improved suppression, because K103N increases efavirenz potency
C) No effect on outcome, because transmitted mutations do not influence treatment-naive patients
D) Toxicity rather than failure, because K103N raises efavirenz concentrations
E) Higher risk of virologic failure, because K103N inactivates efavirenz, effectively reducing a three-drug regimen to two active drugs (functional dual or monotherapy for the affected component)
ANSWER: E
Rationale:
K103N confers high-level resistance to efavirenz; if it is present and undetected, the efavirenz component is inactive, so a nominal three-drug regimen delivers only two active drugs. Integrating transmitted resistance with the functional-monotherapy principle predicts a higher risk of virologic failure and further resistance, which is why baseline genotype testing is recommended.
Option A: Option A is incorrect: the number of drugs prescribed is irrelevant if one is inactive against the patient's virus.
Option B: Option B inverts the effect: K103N reduces, not increases, efavirenz activity.
Option C: Option C is incorrect: transmitted mutations very much affect treatment-naive patients.
Option D: Option D is incorrect: K103N causes loss of efavirenz activity, not elevated concentrations or toxicity.
9. A patient co-infected with HIV and hepatitis B virus (HBV) also has early chronic kidney disease and low bone density. Integrating the dual antiviral activity of the tenofovir/emtricitabine backbone with the pharmacokinetic differences between the two tenofovir prodrugs, which backbone choice best serves all three concerns?
A) Drop tenofovir entirely and use emtricitabine alone, since one HBV-active drug is enough
B) Use tenofovir alafenamide (TAF) with emtricitabine, preserving dual HIV/HBV coverage while minimizing renal and bone toxicity through TAF's lower systemic tenofovir exposure
C) Use high-dose tenofovir disoproxil fumarate (TDF) with emtricitabine to maximize HBV suppression despite renal risk
D) Use abacavir with emtricitabine, since abacavir spares the kidney and also treats HBV
E) Use zidovudine with emtricitabine to avoid tenofovir while keeping marrow monitoring
ANSWER: B
Rationale:
This patient needs continued dual HIV/HBV coverage (tenofovir plus emtricitabine) but also has renal and bone risk. TAF delivers tenofovir with much lower systemic exposure than TDF, retaining HBV and HIV activity while minimizing renal and bone toxicity, so TAF plus emtricitabine best satisfies all three concerns.
Option A: Option A is incorrect: dropping tenofovir weakens HBV coverage and risks a flare; single-agent anti-HBV coverage is inadequate and invites resistance.
Option C: Option C is incorrect: high-dose TDF raises systemic tenofovir exposure and worsens the renal and bone problems.
Option D: Option D is incorrect: abacavir is not an anti-HBV agent, so it fails the HBV requirement.
Option E: Option E is incorrect: zidovudine does not treat HBV and adds marrow toxicity, failing the co-infection need.
10. A patient being considered for a rilpivirine-based regimen takes a daily proton pump inhibitor (PPI) for severe reflux and also requires a medication known to prolong the QT interval. Integrating rilpivirine's absorption requirements and its cardiac caution, what is the best assessment?
A) Rilpivirine is ideal here because PPIs improve its absorption and it shortens the QT interval
B) Only the QT issue matters; the PPI can simply be continued alongside rilpivirine
C) Neither issue is relevant to rilpivirine, so the regimen can proceed unchanged
D) Rilpivirine is a poor fit: the PPI is contraindicated because acid suppression reduces rilpivirine absorption to subtherapeutic levels, and added caution applies when combining rilpivirine with other QT-prolonging drugs, so an alternative agent is preferable
E) Rilpivirine should be given intravenously to bypass the absorption problem and the QT concern
ANSWER: D
Rationale:
Rilpivirine absorption depends on gastric acidity, and PPIs are contraindicated because they reduce its absorption to subtherapeutic levels regardless of timing; rilpivirine also warrants caution with other QT-prolonging agents. Integrating both issues, rilpivirine is a poor fit for this patient and an alternative agent is preferable.
Option A: Option A is incorrect on both counts: PPIs impair rilpivirine absorption, and rilpivirine can prolong, not shorten, QTc at high exposure.
Option B: Option B is incorrect: the PPI interaction is a genuine contraindication, not a detail to ignore.
Option C: Option C is incorrect: both the absorption and QT issues are directly relevant.
Option E: Option E is incorrect: rilpivirine is an oral agent, and an intravenous route is not an available or appropriate solution.
11. A clinician reviewing the historical decline of lactic acidosis as a complication of NRTI therapy asks why modern backbones rarely cause it. Integrating the mechanism of mitochondrial toxicity with the agent-specific risk hierarchy, which explanation is correct?
A) Mitochondrial toxicity arises from inhibition of mitochondrial DNA polymerase gamma, and the highest-affinity agents (stavudine and didanosine, with zidovudine next) have been largely removed from modern regimens, while current backbone agents such as tenofovir, emtricitabine, and lamivudine have negligible mitochondrial toxicity at therapeutic levels
B) Lactic acidosis was caused by NNRTIs, which are now used less often
C) Modern agents chelate lactate directly, preventing accumulation
D) Mitochondrial toxicity reflects nuclear DNA polymerase inhibition, which newer drugs avoid
E) Lactic acidosis declined only because monitoring stopped, not because of any pharmacological change
ANSWER: A
Rationale:
NRTI mitochondrial toxicity comes from inhibition of mitochondrial DNA polymerase gamma; the highest-affinity agents, stavudine and didanosine (with zidovudine next in the hierarchy), have largely been removed from modern regimens, while current backbone agents (tenofovir, emtricitabine, lamivudine) have negligible mitochondrial toxicity at therapeutic concentrations. Integrating mechanism and risk hierarchy explains the decline.
Option B: Option B is incorrect: lactic acidosis is an NRTI mitochondrial effect, not an NNRTI effect.
Option C: Option C is incorrect: modern agents do not chelate lactate; the change is lower pol-gamma inhibition.
Option D: Option D is incorrect: the relevant target is mitochondrial, not nuclear, DNA polymerase.
Option E: Option E is incorrect: the decline reflects a real pharmacological shift away from high-risk agents, not merely reduced monitoring.
12. A patient repeatedly cycles between undetectable viral load and intermittent viremia around 1,000 copies/mL due to inconsistent adherence. Integrating the rationale for full virologic suppression with the dynamics of resistance selection, why is this pattern particularly dangerous?
A) Intermittent viremia is harmless as long as the average viral load is low
B) Low-level viremia eradicates the latent reservoir, curing the infection
C) Partial drug exposure during ongoing replication exerts selective pressure that enriches pre-existing resistant mutants, so repeated incomplete suppression drives stepwise accumulation of resistance and threatens future regimens
D) Resistance only develops when the viral load exceeds one million copies/mL, so this level is safe
E) Adherence has no effect on resistance because resistance is purely random
ANSWER: C
Rationale:
Because resistant mutants pre-exist in the viral quasispecies, drug exposure that does not fully suppress replication selectively enriches them; repeated cycles of partial suppression therefore drive stepwise accumulation of resistance, which is exactly why the goal is durable full suppression below the limit of detection. This integrates the suppression rationale with resistance dynamics.
Option A: Option A is incorrect: it is incomplete suppression during active replication, not the average level, that drives selection.
Option B: Option B is incorrect: low-level viremia does not eradicate the latent reservoir or cure infection.
Option D: Option D is incorrect: resistance selection occurs at modest replication levels, not only at extreme viral loads.
Option E: Option E is incorrect: adherence strongly influences resistance because it determines whether replication is suppressed.
13. A patient with complex polypharmacy (multiple CYP3A4-dependent medications) needs HIV therapy, and the team wants to minimize drug-interaction complexity from the antiretroviral reverse transcriptase components. Integrating the metabolic profiles of the two reverse transcriptase inhibitor classes, which statement best guides the choice?
A) NRTIs are major CYP3A4 inducers, so they are the larger source of interactions
B) First-generation NNRTIs are interaction-free, so efavirenz is the safest choice in polypharmacy
C) Both classes are equally heavy CYP3A4 modulators, so the choice makes no difference
D) NNRTIs have no metabolic interactions, while NRTIs are the class that induces CYP enzymes
E) NRTIs are largely free of cytochrome P450 (CYP) interactions and act mainly through renal transporters, whereas first-generation NNRTIs such as efavirenz are CYP3A4 inducers; minimizing CYP-related complexity favors relying on the NRTI backbone and choosing a non-inducing third agent
ANSWER: E
Rationale:
NRTIs are not CYP substrates, inhibitors, or inducers, so their interactions are mainly at renal transporters; first-generation NNRTIs such as efavirenz are CYP3A4 inducers that perturb many co-medications. Integrating these profiles, CYP-related complexity is minimized by relying on the interaction-light NRTI backbone and selecting a non-inducing third agent rather than a first-generation NNRTI.
Option A: Option A inverts the picture: NRTIs are not CYP3A4 inducers.
Option B: Option B is incorrect: efavirenz is a CYP3A4 inducer and a major interaction source, not interaction-free.
Option C: Option C is incorrect: the two classes differ markedly, with NRTIs being CYP-light and first-generation NNRTIs CYP-active.
Option D: Option D inverts both halves: NNRTIs (not NRTIs) carry the CYP interactions, and NRTIs are the CYP-light class.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.